Informations

 At the 2025 European Society for Medical Oncology (ESMO) Annual Congress, Chinese innovative drugs and clinical research drew global attention. During the meeting, Xichun Hu, Professor at Fudan University Shanghai Cancer Center, presented a Late-Breaking Abstract (LBA) detailing the pivotal phase III study in which China’s first original HER2-targeted antibody–drug conjugate (ADC), A166 (budotituzumab vedotin), successfully challenged T-DM1 in the second-line setting for HER2-positive breast cancer. Based on this study, A166 received approval from the National Medical Products Administration (NMPA) on October 17, 2025, bringing a new standard-of-care option to clinical practice. 

Hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2−) breast cancer accounts for approximately 70% of all breast cancer cases. Treatment for this subtype has entered the era of precision “endocrine plus” therapy. Endocrine therapy combined with CDK4/6 inhibitors has become the standard first-line treatment for advanced disease; however, differences in efficacy and safety exist among…

The study not only fills a gap in international guidelines regarding treatment strategies for advanced HCC, but also injects fresh insight into global HCC management through a “China‑led approach,”marking China’s…

In recent years, advances in systemic therapy have offered hope for advanced liver cancer patients, but traditional single treatments remain limited, highlighting the need for new approaches. Combining systemic therapy with local treatments has become a key trend, with multidisciplinary team (MDT) collaboration now a global standard. Experts from surgery, interventional radiology, oncology, and more…